Identifying potential targets for prevention and treatment of amyotrophic lateral sclerosis based on a screen of medicare prescription drugs

References

• Turner MR, Hardiman O, Benatar M, Brooks BR, Chio A, de Carvalho M. Controversies and priorities in amyotrophic lateral sclerosis. Lancet Neurol. 2013;12:310–22.
   PubMed Web of Science ®Google Scholar
• Al-Chalabi A, Hardiman O. The epidemiology of ALS: a conspiracy of genes, environment and time. Nat Rev Neurol. 2013;9:617–28.
   PubMed Web of Science ®Google Scholar
• Mehta P, Kaye W, Raymond J, Punjani R, Larson T, Cohen J, et al. Prevalence of amyotrophic lateral sclerosis — United States, 2015. MMWR Morb Mortal Wkly Rep. 2018;67:1285–9.
   PubMed Web of Science ®Google Scholar
• Andersen PM, Al-Chalabi A. Clinical genetics of amyotrophic lateral sclerosis: what do we really know? Nat Rev Neurol. 2011;7:603–15.
   PubMed Web of Science ®Google Scholar
• Oskarsson B, Gendron TF, Staff NP. Amyotrophic lateral sclerosis: an update for 2018. Mayo Clin Proc. 2018; 93:1617–28.
   PubMed Web of Science ®Google Scholar
• Martinez A, Palomo Ruiz MD, Perez DI, Gil C. Drugs in clinical development for the treatment of amyotrophic lateral sclerosis. Expert Opin Investig Drugs. 2017;26:403–14.
   PubMed Web of Science ®Google Scholar
• Freedman DM, Kuncl RW, Cahoon EK, Rivera DR, Pfeiffer RM. Relationship of statins and other cholesterol-lowering medications and risk of amyotrophic lateral sclerosis in the US elderly. Amyotroph Lat Scler Fr. 2018; 19:538–46.
   PubMed Web of Science ®Google Scholar
• Engels EA, Pfeiffer RM, Ricker W, Wheeler W, Parsons R, Warren JL. Use of surveillance, epidemiology, and end results-medicare data to conduct case-control studies of cancer among the US elderly. Am J Epidemiol. 2011;174:860–70.
   PubMed Web of Science ®Google Scholar
• Oskarsson B, Horton DK, Mitsumoto H. Potential environmental factors in amyotrophic lateral sclerosis. Neurol Clin. 2015;33:877–88.
   PubMed Web of Science ®Google Scholar
• Bonito AJ, Bann C ,Eicheldinger C, Carpenter L. Creation of new race-ethnicity codes and socioeconomic status (SES) indicators for Medicare beneficiaries. Rockville, MD: Agency for Healthcare Research and Quality and Center for Medicare and Medicaid Services; 2008.
   Google Scholar
• Traxinger K, Kelly C, Johnson BA, Lyles RH, Glass JD. Prognosis and epidemiology of amyotrophic lateral sclerosis: analysis of a clinic population, 1997-2011. Neurol Clin Pract. 2013;3:313–20.
   PubMedGoogle Scholar
• Blasco H, Guennoc AM, Veyrat-Durebex C, Gordon PH, Andres CR, Camu W, et al. Amyotrophic lateral sclerosis: a hormonal condition?. Amyotroph Lateral Scler. 2012; 13:585–8.
   PubMed Web of Science ®Google Scholar
• Kioumourtzoglou MA, Rotem RS, Seals RM, Gredal O, Hansen J, Weisskopf MG. Diabetes mellitus, obesity, and diagnosis of amyotrophic lateral sclerosis: a population-based study. JAMA Neurol. 2015;72:905–11.
   PubMed Web of Science ®Google Scholar
• Mariosa D, Kamel F, Bellocco R, Ye W, Fang F. Association between diabetes and amyotrophic lateral sclerosis in Sweden. Eur J Neurol. 2015;22:1436–42.
   PubMed Web of Science ®Google Scholar
• Tsai CP, Lee JKW, Lee C. Type II diabetes mellitus and the incidence of amyotrophic lateral sclerosis. J Neurol. 2019; 266:2233.
   PubMed Web of Science ®Google Scholar
• D'Ovidio F, d'Errico A, Carna P, Calvo A, Costa G, Chio A. The role of pre-morbid diabetes on developing amyotrophic lateral sclerosis. Eur J Neurol. 2018; 25:164–70.
   PubMed Web of Science ®Google Scholar
• Zeng P, Zhou X. Causal effects of blood lipids on amyotrophic lateral sclerosis: a mendelian randomization study [Internet]. Hum Mol Genet. 2019; 28:688–97.
   PubMed Web of Science ®Google Scholar
• Bandres-Ciga S, Noyce AJ, Hemani G, Nicolas A, Calvo A, Mora G, et al. Shared polygenic risk and causal inferences in amyotrophic lateral sclerosis. Ann Neurol. 2019;85:470–81.
   PubMed Web of Science ®Google Scholar
• Osman EY, Washington CW, Simon ME, Megiddo D, Greif H, Lorson CL. Analysis of azithromycin monohydrate as a single or a combinatorial therapy in a mouse model of severe spinal muscular atrophy. J Neuromuscul Dis. 2017;4:237–49.
   PubMedGoogle Scholar
• Kaur P, Muthuraman A, Kaur M. The implications of angiotensin-converting enzymes and their modulators in neurodegenerative disorders: current and future perspectives. ACS Chem Neurosci. 2015;6:508–21.
   PubMed Web of Science ®Google Scholar
• Lin FC, Tsai CP, Kuang-Wu Lee J, Wu MT, Tzu-Chi Lee C. Angiotensin-converting enzyme inhibitors and amyotrophic lateral sclerosis risk. JAMA Neurol. 2015;72:40–8.
   PubMed Web of Science ®Google Scholar
• Agarwal S, Yadav A, Chaturvedi RK. Peroxisome proliferator-activated receptors (PPARs) as therapeutic target in neurodegenerative disorders. Biochem Biophys Res Commun. 2017;483:116–1177.
   Web of Science ®Google Scholar
• Mosley RL, Gendelman HE. Control of neuroinflammation as a therapeutic strategy for amyotrophic lateral sclerosis and other neurodegenerative disorders. Exp Neurol. 2010;222:1–5.
   PubMed Web of Science ®Google Scholar
• Zufirí M, Gil-Bea FJ, Fernández-Torrón R, Poza JJ, Muñoz-Blanco JL, Rojas-García R, et al. ALS: A bucket of genes, environment, metabolism and unknown ingredients. Prog Neurobiol. 2016;142:104–29.
   PubMed Web of Science ®Google Scholar
• Saldanha C, Duncan K, Walters B. Neuroprotective actions of brain aromatase. Front Neuroendocrinol. 2009;30:106.
   PubMed Web of Science ®Google Scholar
• Rooney JPK, Visser AE, D'Ovidio F, Vermeulen R, Beghi E, Chio A, et al. A case-control study of hormonal exposures as etiologic factors for ALS in women. Neurology. 2017;89:1283–90.
   PubMed Web of Science ®Google Scholar
• Yan L, Liu Y, Sun C, Zheng Q, Hao P, Zhai J, et al. Effects of ovariectomy in an hSOD1-G93A transgenic mouse model of amyotrophic lateral sclerosis (ALS). Med Sci Monit. 2018;24:678–86.
   PubMed Web of Science ®Google Scholar
• Orsini M, Oliveira AB, Nascimento OJM, Reis CHM, Leite MAA, De Souza JA, et al. Amyotrophic lateral sclerosis: new perpectives and update. Neurol Int. 2015;7:5885.
   PubMed Web of Science ®Google Scholar
• Zhou F, Dong H, Liu Y, Yan L, Sun C, Hao P, et al. Raloxifene, a promising estrogen replacement, limits TDP-25 cell death by enhancing autophagy and suppressing apoptosis. Brain Res Bull. 2018; 140:281–90.
   PubMed Web of Science ®Google Scholar
• Gargiulo-Monachelli GM, Sivori M, Meyer M, Sica R, De Nicola A, Gonzalez-Deniselle MC. Circulating gonadal and adrenal steroids in amyotrophic lateral sclerosis: possible markers of susceptibility and outcome. Horm Metab Res. 2014;46:433–9.
   PubMed Web of Science ®Google Scholar
• Van Es MA, Hardiman O, Chio A, Al-Chalabi A, Pasterkamp RJ, Veldink JH, et al. Amyotrophic lateral sclerosis. Lancet. 2017;390:2084–98.
   PubMed Web of Science ®Google Scholar
• Traynor BJ, Codd MB, Corr B, Forde C, Frost E, Hardiman OM. Clinical features of amyotrophic lateral sclerosis according to the El Escorial and Airlie House diagnostic criteria - a population-based study. Arch Neurol. 2000;57:1171–6.
   PubMed Web of Science ®Google Scholar
• Ingre C, Roos RM, Piehl F, Kamel F, Fang FC. Risk factors for amyotrophic lateral sclerosis. Clin Epidemiol. 2015;7:181–93.
   PubMed Web of Science ®Google Scholar